Does Finasteride Actually Regrow Hair? Real Response Rates

Finasteride 1 mg (brand name Propecia, also sold generically) is a 5-alpha-reductase type II inhibitor FDA-approved for male androgenetic alopecia (AGA). It is a different drug from dutasteride, which inhibits both type I and type II 5-alpha-reductase and is FDA-approved only for benign prostatic hyperplasia (BPH), not hair loss. This article is about the oral 1 mg AGA indication, not the 5 mg finasteride tablet used off-label for BPH-related purposes or the topical formulations sold through compounding pharmacies.

The direct answer, and its limits

Finasteride's original placebo-controlled registration trials, which formed the basis of FDA approval, found that most treated men stopped losing hair and roughly two-thirds gained measurable hair count over two years, compared with a small minority of placebo-treated men. That is controlled-trial evidence: standardized photography, blinded grading, and a defined target zone, not self-report. Patient-reported response rates on consumer platforms and social forums cluster in a broadly similar but somewhat lower range, which is consistent with lower real-world adherence, earlier-than-recommended discontinuation, and the self-selecting nature of who bothers to post online. Neither data source proves the other wrong; they are answering slightly different questions, and the exact percentages from the older trials should be checked against the current FDA label before being restated as fixed figures.

What is established, what is plausible, and what is not established

Established, with reasonable confidence:

• Finasteride 1 mg lowers DHT and, in controlled trials, reduced the proportion of men who lost further hair over two years compared with placebo.
• A meaningful minority of users do not respond even with confirmed adherence over 12 months or more.
• Benefit is contingent on continued use; hair gained on the drug is generally lost over the months following discontinuation, based on longer-term follow-up data described in the literature.
• A temporary increase in shedding in the first months of use is a recognized, described phenomenon and is not itself a sign of treatment failure.

Plausible but not rigorously established for individual prediction:

• That earlier initiation, milder baseline loss, and vertex-predominant (rather than frontal) patterns predict a better response. This pattern appears across multiple lines of evidence but has not been turned into a validated individual prediction tool.
• That genetic markers (androgen receptor sensitivity, 5-alpha-reductase gene variants) influence response. Research has explored this, but no commercially available genetic test has FDA clearance to predict individual finasteride response.

Not established:

• A validated way to predict, before starting treatment, which specific patients will respond.
• A confirmed mechanistic explanation or reliable incidence estimate for persistent sexual or mood symptoms after stopping finasteride (sometimes called post-finasteride syndrome). Case reports and some observational signals exist; a confirmed epidemiological framework does not.
• Any FDA-approved role for finasteride in women, or for dutasteride in AGA at all. Both are off-label uses regardless of any published data.

Clinical trial evidence: what the registration studies found

The original Phase III trials that supported FDA approval enrolled young and middle-aged men with mild-to-moderate vertex or frontal thinning and followed them for two years using standardized scalp photography, blinded expert grading, and hair counts in a defined 1 cm² target zone. The commonly cited headline results are that the large majority of treated men had no further measurable loss, and roughly two-thirds showed visible improvement, versus a small minority in the placebo group. These figures are widely repeated in dermatology references and appear consistent with FDA-reviewed labeling, but this article treats the exact percentages as needing verification against the current label text rather than restating decades-old secondary summaries as fixed numbers.

A longer open-label follow-up reportedly found that men who had responded by year two generally maintained that benefit with continued use through year five, and that stopping the drug was followed by loss of the gained hair over roughly the following year. This pattern, benefit tied to continued use, not a one-time cure, is the single most clinically important thing to communicate to a patient weighing whether to start.

Real-world response: what forums and review platforms actually tell you

Consumer review sites and hair-loss forums (including large threads on Reddit's r/tressless) generally describe a majority of users reporting stabilization or improvement, with a meaningful minority reporting no change and a smaller minority reporting apparent worsening. These numbers should be read as directional, not precise. They come from self-selected respondents, use no standardized photography or blinded grading, and are vulnerable to two well-known distortions:

• People who are satisfied often stop posting, while people who are frustrated post more, which can skew visible community sentiment in either direction depending on the forum and moment.
• A subset of "it didn't work" reports come from men who stopped during the early shedding phase (commonly described as weeks 6 to 16 of use) or who evaluated the drug at 3 to 5 months, well short of the 12-month minimum trial period recommended before concluding non-response.

None of this means forum and review data are useless. It means they answer "what do people report" rather than "what does a controlled comparison show," and the two should not be presented as interchangeable statistics.

An evidence-review framework: separating reported experience from controlled evidence

Use this framework before accepting any specific finasteride "success rate" claim, whether from a forum, a review site, or a marketing page.

The rule this framework encodes: a claim only earns a specific number in patient-facing material if it comes from a source that can be checked against the current, verifiable literature. Everything else should be described directionally, with its evidence tier stated plainly.

Who tends to respond better, and why that is not a promise

Several patterns show up repeatedly across the literature and clinical experience, though none amounts to a validated prediction tool for an individual patient.

Pattern and stage of loss. Men with earlier-stage vertex thinning tend to show a stronger response than men with advanced, long-standing frontal recession or near-complete vertex loss. Follicles that have been miniaturized for years have less capacity to recover, and men at the most advanced Norwood stages typically see stabilization at best, not regrowth, because functional follicles may no longer be present to respond.

Age at initiation. Starting treatment earlier in the course of hair loss is generally associated with a better response, plausibly because follicles have had less time to miniaturize. Specific comparative percentages by age band should be checked against the primary study before being quoted to a patient.

Duration and adherence. The single largest modifiable factor in real-world "failure" is stopping too early or taking the drug inconsistently. A full trial requires daily use for at least 12 months, and some clinicians extend that to 18 months before judging frontal-pattern response. Retrospective prescription-refill data have suggested that a substantial share of men who start finasteride are no longer filling the prescription by month 12, which on its own would explain much of the gap between trial-reported and forum-reported response rates.

Genetics. Androgen receptor sensitivity and 5-alpha-reductase gene variation have been studied as possible predictors of response. Research signals exist, but no FDA-cleared commercial test currently predicts individual finasteride response, and ordering an unvalidated genetic panel for this purpose is not currently supported by evidence.

Side effects and what they do to the "effective" response rate

A drug a patient stops taking because of side effects is a non-responder from that patient's point of view, regardless of what it might have done biologically.

Sexual side effects (reduced libido, erectile difficulty, ejaculatory changes) were reported more often in finasteride-treated men than in placebo-treated men in the original registration trials. Most reported cases resolved with continued use or after stopping. A smaller, more contested body of literature and patient reports describes symptoms that persist after discontinuation, sometimes called post-finasteride syndrome. This is not a confirmed, mechanistically established diagnosis with a known incidence rate; it is a real concern raised in case reports and some observational work, and it deserves an honest mention rather than dismissal or overstatement. Anyone considering finasteride should be told plainly that rare, persistent sexual or mood-related symptoms after stopping have been reported, that the true incidence is not well established, and that this uncertainty is part of the informed decision, not a settled statistic.

Mood-related reports (low mood, "brain fog") also appear in patient forums. Observational registry research has explored a possible association between finasteride use and depression diagnosis, but such studies cannot fully separate the drug's effect from the psychological burden of hair loss itself, and any specific effect-size figure should be checked against the primary paper before being repeated as established.

Discontinuation specifically due to side effects appears to be uncommon in the original trial populations, but real-world discontinuation for any reason (side effects, cost, forgetting, disappointment with pace of results) is common enough to be the dominant explanation for lower real-world response figures compared with trial data.

How finasteride compares with other options

Versus topical minoxidil. Minoxidil is the other FDA-approved monotherapy for AGA in men, working through a different, less fully understood mechanism than 5-alpha-reductase inhibition. Systematic comparisons in the dermatology literature generally favor finasteride on hair-count outcomes at 12 months among men, and combining the two is generally considered more effective than either alone in randomized comparisons, though exact effect sizes from any specific trial should be verified before being quoted.

Versus dutasteride. Dutasteride inhibits both type I and type II 5-alpha-reductase and lowers DHT more completely than finasteride. It is FDA-approved only for benign prostatic hyperplasia, not for hair loss, so any use for AGA is off-label. A 2025 real-world retrospective study comparing finasteride and dutasteride outcomes in a BPH population reported differences in comparative effectiveness and safety between the two drugs (Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Benign Prostatic Hyperplasia, 2025). That study's population had enlarged prostate, not hair loss, and its findings do not establish a comparative hair-regrowth response rate between the two drugs. Older, smaller randomized comparisons in AGA populations have suggested dutasteride may produce somewhat greater hair-count gains than finasteride, but with a higher side-effect burden and no FDA approval for this use, which is a meaningful boundary a patient should understand before considering an off-label switch.

Topical finasteride. Topical finasteride solutions are available through compounding pharmacies and have been studied as a way to achieve local scalp effect with lower systemic DHT suppression than the oral tablet. These formulations are not FDA-approved as standalone products, and comparative response-rate claims for topical versus oral finasteride should be treated as investigational rather than settled.

What "no response" actually means before you conclude the drug failed

Roughly one in ten to one in six men taking finasteride 1 mg for a full year will show no measurable improvement even with confirmed adherence. Before concluding non-response, it is reasonable to confirm:

1. Actual daily adherence, not intended adherence
2. Duration of at least 12 months, and up to 18 months for frontal-pattern loss specifically
3. Alternative or contributing diagnoses, including telogen effluvium, alopecia areata, diffuse unpatterned alopecia, thyroid dysfunction, or iron deficiency, any of which can cause or worsen shedding independent of androgenetic alopecia and should be evaluated by a clinician rather than assumed

For confirmed non-responders with adequate duration and adherence, reasonable next discussions with a clinician include adding topical minoxidil, considering off-label dutasteride with an explicit discussion of its unapproved status for this use, low-level laser therapy as an adjunct, or a hair transplant evaluation if follicular reserve is confirmed.

A practical way to judge your own results at 3, 6, and 12 months

Judging response from memory or inconsistent phone photos is unreliable. A more consistent approach:

Month 3. Expect no visible improvement yet. The goal at this stage is checking tolerability and confirming adherence, not judging efficacy. A temporary increase in shedding during the first few months is a recognized part of the process and is not a reason to stop on its own, though any new or concerning symptom should be discussed with a prescriber.

Month 6. Some men notice reduced shedding or a subjective sense of stabilization. Visible regrowth is possible but not expected yet for most. This is a good point to take standardized photographs (same lighting, same angle, hair wet and combed to expose the scalp) to serve as a baseline for the 12-month comparison.

Month 12. This is the meaningful decision point. Compare photographs taken under identical conditions at month 0 and month 12. If there is no visible difference and a hair-pull test still suggests active shedding, that is the point to have a clinical conversation about non-response rather than waiting indefinitely.

Questions people actually ask

What to do with this information

If you are trying to decide whether finasteride is working for you, the most useful step is not another forum search but a structured 12-month comparison: confirmed daily adherence, a baseline photograph taken before starting, and a same-conditions photograph at month 12, reviewed with a prescriber alongside a check for other causes of shedding. If you are considering starting the drug, ask your prescriber directly about the uncertainty around persistent post-discontinuation symptoms rather than relying on either reassurance or alarm from online sources, since neither position is currently backed by a settled epidemiological answer.

If you experience new sexual, mood, or neurological symptoms while taking finasteride, or symptoms that persist after stopping, that is a reason for a direct conversation with a prescriber rather than a wait-and-see approach through further self-research.

References

• Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Benign Prostatic Hyperplasia: A Real-World Retrospective Study (2025). https://pubmed.ncbi.nlm.nih.gov/41303781/ (note: this study population has benign prostatic hyperplasia, not androgenetic alopecia; it does not establish comparative hair-regrowth response rates)
• Current FDA-approved prescribing information for finasteride 1 mg should be checked directly at fda.gov before restating specific trial percentages as current fact.

This article summarizes general patterns from published and commonly cited finasteride research and is not individualized medical advice. Specific percentages attributed to older trials should be verified against the current FDA label and primary literature before being used in clinical or patient-facing material. This draft is pending qualified medical review.